Skip to main content

Table 1 Clinicopathological parameters for the clinical tumour set

From: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

  Number Percentage
Tumour grade   
   Grade 1 2 2.6
   Grade 2 29 37.7
   Grade 3 43 55.8
   Not known 3 3.9
Oestrogen receptor status   
   Positive 46 59.7
   Negative 31 40.3
Epidermal growth factor receptor (membrane) status   
   Positive 43 55.8
   Negative 31 40.3
   Not known 3 3.9
erbB2 (membrane) status   
   Positive 19 71.4
   Negative 55 24.7
   Not known 3 3.9
erbB3 (membrane) status   
   Positive 61 79.3
   Negative 9 11.7
   Not known 7 9.1
Menopausal status   
   Premenopausal 23 31.1
   Postmenopausal 51 68.9
   Not known 3 3.9
Site of disease   
   Locally advanced 29 39.2
   Metastatic 45 60.8
   Not known 3 3.9
Ki-67 index   
   0 10 13
   <10 15 19.5
   10–30 52 67.5